Why More Patients Are Choosing Cannabis Over Opioids

Photo by MART PRODUCTION via Pexels.

A patient describes, in an essay NORML published on July 6, 2026, the moment they decided to stop refilling an opioid prescription and try cannabis instead. It's a personal account, but it's backed by something concrete: a newly published fibromyalgia study cited in the piece found that 70% of a treatment group achieved clinically meaningful pain relief with cannabis. That's not a fringe result anymore. It's one entry in a growing stack of research showing cannabis can do real work in chronic pain management, sometimes displacing opioids entirely.

What makes this particular essay worth reading right now isn't just the personal narrative -- it's the timing. This individual's choice sits inside a much bigger, messier federal process. Just weeks before the essay ran, DEA administrative hearings on marijuana's federal schedule wrapped up in mid-July 2026, closing out more than two weeks of testimony. One person's decision to swap pills for flower or tincture is a small data point, but it's happening against the backdrop of a rescheduling fight that will determine how many other patients get the same option, and how easily.

The Rescheduling Backdrop Patients Are Reacting To

Photo by David Guerrero via Pexels.

The legal groundwork for this shift goes back to December 18, 2025, when President Trump signed an executive order directing the Attorney General to expedite marijuana rescheduling. That order set a clock running on a process that had stalled for years under the prior administration's review. By April 23, 2026, the DOJ and DEA delivered: a final order moved FDA-approved and state-licensed medical marijuana products into Schedule III of the Controlled Substances Act, alongside drugs like ketamine and anabolic steroids.

That move matters, but it's narrower than a lot of people assume. Recreational cannabis, or medical cannabis obtained without a state-issued license, remains Schedule I -- still officially defined as having no accepted medical use and a high potential for abuse. That split creates a genuine gray zone: a patient in a state-licensed medical program is now dealing with a substance the federal government treats very differently than the same plant purchased at a recreational dispensary down the street, or grown without any license at all.

The story didn't end there. A follow-up hearing on broader rescheduling questions ran from June 29 through July 15, 2026, spanning 17 days of testimony before closing arguments. Chief Administrative Law Judge Derek Julius then set August 17, 2026 as the deadline for parties to file optional post-hearing briefs, capped at 50 pages. That deadline is the next real checkpoint. Whatever Julius eventually recommends will shape whether Schedule III becomes a permanent, narrow medical carve-out or a stepping stone toward something broader. Nothing is settled yet, and patients making decisions right now are doing so under rules that could still shift.

Who Got a Seat at the Table -- and Who Didn't

Photo by Wesley Tingey via Unsplash.

Who the DEA invited to testify tells you almost as much as what got said. The agency's witness list for the summer hearings leaned heavily toward organizations and state officials who've historically opposed broader cannabis reform -- voices likely to reinforce a cautious, narrow reading of what rescheduling should accomplish. Groups that have spent years building the evidentiary case for looser restrictions, including NORML and the Marijuana Policy Project, were excluded from presenting evidence at the hearing itself.

NORML didn't let that go quietly. On June 19, 2026, the organization sent a letter to the DEA seeking reconsideration, arguing the agency should be weighing full descheduling rather than settling for Schedule III. Their position is straightforward: Schedule III still leaves cannabis under federal criminal law in ways that complicate banking, research, interstate commerce, and everyday patient access, especially for the many people who use cannabis outside a formal medical program.

The fight isn't confined to the hearing room, either. The D.C. Circuit Court of Appeals is separately weighing multiple legal challenges to the April Final Order, filed by parties on both sides of the reform debate -- some arguing rescheduling didn't go far enough, others arguing the DEA overstepped its authority. That litigation runs on its own timeline, independent of Julius's process.

This procedural wrangling can feel like inside baseball, but it determines something patients actually feel: whether the endpoint is a slightly loosened medical framework limited to state-licensed programs, or a genuinely broader shift in how the law treats cannabis use of any kind. Who gets a seat at the table shapes what's on the menu when the table finally clears.

What the Pain Research Actually Shows

Across multiple studies, cannabis therapy was linked to substantial reductions in opioid use, with some cohorts—like UPenn's chronic pain patients—reporting up to 100% decline, while state-level data showed a more modest 10% drop.

Strip away the politics and the research base for cannabis as a pain-management and opioid-reduction tool has gotten considerably harder to wave off. The fibromyalgia study referenced in the NORML essay found 70% of a treatment group reached clinically meaningful pain relief -- a threshold researchers use because it reflects a change patients actually notice in daily function, not just a modest shift on a pain scale.

Population-level data backs this up. A February 2026 study out of Boston University looked at people who inject drugs and found that in states with legal medical and recreational cannabis, daily opioid use dropped 9 to 11 percentage points compared to states with medical-only programs. That's a meaningful gap for a population at especially high overdose risk.

Clinical studies tell a similar story at the individual level. A May 2026 University of Pennsylvania study followed 29 chronic pain patients over five months of cannabis therapy and found both reduced pain scores and lower daily opioid use. Another 2026 study reported patients cutting opioid use by an average of 83.9%, with 61% of participants stopping opioids altogether -- a striking figure for a chronic pain population, where opioid tapering is notoriously difficult.

Maybe the most persuasive number comes from a five-year Biomedicines study tracking chronic low back pain patients: opioid use started at 100% of the study population at baseline and fell to just 4.6% after five years of cannabis-inclusive treatment. Five years is a long enough window to rule out a short-term placebo effect. Taken together, this isn't one study or one anecdote -- it's a pattern showing up across different patient populations, different pain conditions, and different research teams.

Why Patients Are Making This Switch Now

Photo by RDNE Stock project via Pexels.

None of this means recreational cannabis is now legal nationwide, or that every patient's path just got simpler. Schedule III doesn't do that. What it does is signal that the federal government is backing off some of its hostility toward medical cannabis specifically, and that shift ripples outward in practical ways -- physicians in legal states feel freer to bring cannabis up as an option, patients feel less like they're doing something illicit by asking about it, and insurers and researchers gain a slightly clearer regulatory lane to work within.

The backdrop pushing patients toward this conversation hasn't gone away either. Opioid-related overdose deaths remain a serious public health concern in the U.S., and that reality sits behind a lot of individual decisions to look for alternatives before a chronic pain prescription turns into a long-term dependency. Patients switching to cannabis consistently cite fewer side effects and a lower perceived dependency risk compared to long-term opioid regimens, which lines up with what the research above shows.

Doctors in legal states are increasingly willing to discuss cannabis as harm reduction, either alongside a tapering opioid regimen or as a replacement once pain is stabilized. But access still depends heavily on geography. State medical marijuana programs vary widely in which conditions qualify, how easy it is to get a recommendation, and what products are actually available at a licensed dispensary. A fibromyalgia patient in a state with a broad qualifying-conditions list has a very different experience than one in a state where chronic pain alone doesn't clear the bar. Anyone considering this switch is really navigating two separate systems -- federal schedule and state program -- that don't move in lockstep.

The research pile keeps growing, and it keeps pointing the same direction: cannabis has a real, measurable role to play in getting people off opioids or keeping them from needing opioids in the first place. That's no longer a fringe claim backed by cherry-picked anecdotes -- it's showing up in population studies, clinical trials, and five-year follow-ups alike. The legal system, though, is still lurching toward that reality in pieces, not in one clean move.

Schedule III is a real change, but it's a narrower one than full descheduling would have been, and the fight over who gets to testify, whose evidence counts, and what Judge Julius eventually recommends after August 17 may end up mattering just as much as the reclassification itself. Procedural fights aren't glamorous, but they're where the actual boundaries of patient access get drawn.

If you're weighing this same choice -- cannabis instead of, or alongside, an opioid prescription -- talk to a doctor who knows your history, and look up your own state's medical marijuana law before assuming anything about what's available to you. Federal scheduling status and state-level access are two different questions right now, and they'll probably stay that way for a while longer.